Which injection tends to fit which patient

There is no single “best” knee injection for every patient. The right fit depends on how advanced the osteoarthritis is, what has already been tried, and whether the goal is longer-acting symptom control, a biologic option, or a non-biologic alternative.

Arthrosamid is usually the more natural fit for someone with confirmed knee osteoarthritis who still has pain after exercise, weight management and pain medicines, and who wants one injection with the chance of longer relief. It is generally described for mild-to-moderate wear rather than bone-on-bone disease, and it should be understood as a permanent hydrogel cushioning the joint, not a cartilage repair treatment.

PRP tends to suit earlier-to-moderate OA where a patient is happy to try a biologic injection and accepts that outcomes vary with the preparation and platelet dose. That variability matters: PRP is not one standard product, so durability and response can differ from one clinic’s protocol to another.

HA sits more in the symptom-control category. It may be reasonable in selected earlier-to-moderate cases, especially when a non-biologic option is preferred, but expectations should stay modest and the exact formulation matters.

Severe bone-on-bone arthritis, major malalignment, or instability can reduce the chance that any of these injections works well, so the first question is often whether an injection is sensible at all for the knee being assessed.

What results can you realistically expect

How long relief tends to last

The three injections are best thought of as symptom treatments with different time horizons. In the packet’s evidence, PRP often shows its clearest pain benefit at about 3 to 6 months, with improvement versus placebo in randomised-trial meta-analysis. HA usually gives a more modest benefit in selected earlier-to-moderate knee OA, and the result depends on the product: higher-molecular-weight formulations appear to perform better than lower-molecular-weight ones, with follow-up commonly around 4 to 6 months. Arthrosamid is described in patient-facing clinic material as the longer-acting option, with relief often quoted at about 2 to 3 years from one injection.

Duration is not the same as a guaranteed result. Some people get a clear drop in pain, some notice only partial change, and some do not respond enough to matter. That is true for PRP, HA and Arthrosamid alike, even though the expected pattern differs.

What none of these should be sold as is proven cartilage regrowth for routine knee OA care. In this packet, Arthrosamid is framed as a long-lasting mechanical cushion, PRP as a biologic option with clinically meaningful short-to-medium term improvement, and HA as a symptom-control injection rather than a repair treatment.

How these injections differ in what they do

Why they feel like different treatments

Arthrosamid is not trying to do the same job as PRP or hyaluronic acid. It is a non-resorbable polyacrylamide hydrogel that sits in the joint as a lasting physical buffer, integrating with the synovial lining rather than being absorbed away. That is why it is discussed as a mechanical cushioning filler, not a regenerative treatment.

PRP starts from the patient’s own blood. Its aim is biologic signalling: the platelets release growth factors that may influence inflammation and tissue response. Because PRP is not one standard product, the way it is prepared — including platelet concentration and dose — can change the result from one study or clinic to another.

HA, by contrast, is viscosupplementation. Its role is to improve lubrication and ease symptoms, not to repair cartilage. In plain terms, it is a joint lubricant rather than a scaffold or biologic stimulant.

That difference in mechanism matters when a person is weighing durability and reversibility. A permanent hydrogel may persist for longer, whereas PRP and HA are temporary injections that do not leave a lasting filler behind. For knee OA, that often changes the conversation from “which one is strongest?” to “which kind of symptom control best matches the knee problem and the patient’s tolerance for a long-acting implant-like effect?”

What are the main downsides and uncertainties

Where the uncertainty sits

The main caveat with Arthrosamid is not just whether it helps, but what stays behind. It is a permanent hydrogel in the joint, so counselling needs to include the fact that removal or revision may be difficult if the result is poor or if the knee later needs surgery. That is a different trade-off from PRP or HA, which do not leave a lasting filler in the same way.

PRP brings a different problem: heterogeneity. A 2024 systematic review suggests better outcomes may be linked to a higher platelet dose, which means one clinic’s PRP may not behave like another’s. That makes head-to-head comparisons shaky unless the preparation, platelet concentration and dose are clearly described.

HA has its own inconsistency. A 2025 umbrella review found moderate benefit in early-to-moderate knee OA, but guideline positions still vary, with some organisations supporting selected use and others opposing routine treatment. In practice, recommendations can differ from one clinician to the next.

Across all three injections, response also depends on factors such as OA severity, alignment, weight, activity demands and whether the pain is really coming from the knee joint. That is why uncertainty is normal here, and why a proper assessment before treatment matters.

Cost and NHS access in the UK

Paying for treatment and getting it booked

In real-world clinic settings, Arthrosamid is commonly arranged privately, while the sources reviewed here do not support a clean, UK-wide price comparison for Arthrosamid, PRP or hyaluronic acid. That makes the more useful question not “which is cheapest?” but “what is included in the quoted episode of care?”

For any of these injections, the practical checks are straightforward: whether the consultation, imaging, injection itself and follow-up are priced separately; whether one injection is usually expected or a course is common; and whether the clinic gives a clear explanation of what happens if symptoms do not improve. Prices can also vary by region, consultant and product type, especially for PRP and HA.

The access picture is also uneven. In the sources reviewed, Arthrosamid does not appear to be routinely funded by the NHS for knee osteoarthritis, and PRP is also usually accessed privately. HA may be available in some NHS pathways, but not in a uniform way, so local commissioning and clinician preference still matter.

At MSK Doctors, assessment is consultant-led, no referral is needed, and there is no NHS-style waiting list, which can make the first step simpler when a private appointment is the likely route.

How to decide at your appointment

At the appointment, the most useful question is not “which injection is best?” but “which option matches this knee and this goal?” Five short questions usually help:

• Am I a good candidate based on my OA severity and scan findings?
• What result is realistic for my knee?
• How long might it last?
• What are the main risks or downsides?
• If it does not work, what happens next?

Those answers can point in different directions. A knee with mild-to-moderate wear and a clear wish for a biologic option may suit a different path from a knee where the patient wants a longer-acting mechanical filler, or from a knee with advanced bone-on-bone change. Previous response to rehab also matters: if exercise therapy, weight loss support, bracing or pain management have helped only partly, an injection may be a bridge rather than a final answer.

Budget and access still matter in the UK, especially when treatment is private. Comfort with a permanent implant-like material is relevant for Arthrosamid, while PRP and HA may appeal more to patients who want a non-permanent injection. If symptoms remain severe, or the knee is progressing despite good non-operative care, referral for surgical review may still be the right next step.

The cleanest takeaway is simple: match the injection to the knee, then decide what to do if the first choice falls short. A consultant-led assessment can help keep that decision grounded in severity, goals and access rather than the headline name of the treatment.

1. [1] Author(s) not provided. (2025). PRP injections for the treatment of knee osteoarthritis: The improvement is clinically significant and influenced by platelet concentration: A meta-analysis of randomized controlled trials. https://doi.org/10.1177/03635465241246524 https://doi.org/10.1177/03635465241246524